ELTP is still way undervalued according to this calculation.
Drug Manufacturers Specialty & Generic P/E ratio: 36.45 current average of 47 generic manufacturers
ELTP EPS ($0.0191) x Average P/E Ratio by Industry of (36.45) of 47 generic drug manufacturers = Price Per Share ($0.6962)
ELTP should be at $0.6962 per share even before all these newly revenue to be reported with the recent launches of Methotrexate (~$63 million market), Codeine with Acetaminophen (~$47 million market), and generic Addera by Dexcel Pharma in Israel.
There will be significantly more revenue reported from the launches of generic Percocet (~ $500 million market) launching around 11/18/24 and generic Norco (~$477 million market) launching probably right after the new year.
Elite will have awesome news soon with another record breaking quarterly earnings press release on 11/14/24 and the approval of generic Vyvanse hopeful in November 2024 ($5.1 billion market).
Casual investors will regret giving up their shares so soon recently.
True long ELP investors with do extremely well with their returns when it goes to $5 to $7 within the next 2 years.
Elite’s revenue was ~$56.6 million for the last fiscal year.
Imagine what the share price can be if Elite’s revenue is ~$566 million for all the drugs that are approved for launch and those about to be approved in the pipeline.
10 fold on EPS could be $0.191
$0.191 x 36.45 = $6.962
And this price per share is not even factoring the potential of Elite’s future, Abuse Resistant Technology branded drugs.
1. oxycodone with naltrexone (SequestOx) 2. hydrocodone with naltrexone 3. oxymorphone with naltrexone 4. hydromorphone with naltrexone 5. morphine sulfate with naltrexone
NASDAQ listed is within reach. Buy out offer is plausible.
My current road map with investing in ELTP.
At least 3-5 more press releases are about to be announced in the very near future.
1. Methotrexate $63 million market Just launched on 8/27/24
3. Record earnings conference call 11/14/24 Press release #1
ELTP approved drugs with pending launches:
4. Generic Percocet oxycodone with acetaminophen ~$500 million market Will launch 6-8 weeks after the codeine with acetaminophen launch Press Release #2 As early as 11/18/24
5. Generic Norco hydrocodone with acetaminophen ~$477 million market Will launch 6-8 weeks after the oxycodone with acetaminophen launch Press Release #3 As early as 12/30/24
6. Dolophine/Methadone ~$30 million market Will launch 6-8 weeks after the hydrocodone with acetaminophen launch Press Release #4 As early as 2/14/25
7. Pending approval: Generic Vyvanse ~$5.1 billion market This is the monster news that everyone is waiting for. Hopefully the approvable positive press release will come out by November 2024. Press Release #5
8. Launch of Generic Vyvanse Press Release #6
9. Pending approval for launch: Generic OxyContin ~$720 million market Press release #7
10. Pending approval for launch: Generic Vigabatrin ~$233 Million market Press release #8
9. Pending BE equivalent study result: Generic Concerta ~$1.2 billion market Press release #9
10. Pending submittal: Generic Requip XL or Generic Mirapex ER $12 Million market Press release #10
$63 million - Methotrexate + $47 million - Codeine + $500 million - Percocet + $477 million - Norco + $30 million - Methadone + $720 million -OxyContin + $233 million - Vigabatrin + $12 million - Requip = $2.081 billion
It is in his best interest to continue to provide the rocket fuel for ELTP.
Therefore, we can expect more higher revenue drugs in the pipeline soon for more BE studies since Elite now has money to do so.
Wouldn’t be great if Nasrat or Carter can say something like this on our next conference call, “Our current EPS is $0.0191 per share and the current average P/E for a generic drug manufacturer is 36.45. Based on those two numbers, our stock price should be around $0.6962. However, our EPS will be significantly much higher soon, and ELTP share price could eventually be $6.962 with our target of $566 million per year in revenue.”
Good luck to all you longterm ELTP investors out there. We all will be well rewarded soon with financial freedom.
Many will end up with more shares than they had initially. As long as they get in lowered than where the stop was. Hopefully they had RothIRAs to save on any tax implications.
Market Data 
Markets 
AI
